跳至主要内容
临床试验/NL-OMON20410
NL-OMON20410招募中不适用

Effect of moderate CYP3A4 inhibitor erythromycin on the pharmacokinetics of palbociclib

KI-AV0 个研究点目标入组 14 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Histological or cytological proof of cancer for which palbociclib is considered standard care;
  • Age = 18 years;
  • WHO performance status of 0, 1 or 2;
  • Adequate organ function per judgement of the treating physician;
  • Able and willing to undergo blood sampling for PK analysis.

排除标准

  • Concomitant use of medication(s) which could influence the pharmacokinetics of palbociclib within 14 days or five half-lives of the drug (whichever is shorter) before start of the study, consisting of (but not limited to) CYP3A4-inhibitors/inductors
  • Women who are pregnant or breast feeding;
  • Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the investigator would impair study compliance;
  • Palbociclib related side effects that would require a dose reduction per judgement of the treating physician;
  • QT duration corrected for heart rate > 450 ms or > 480 ms for subjects with bundle branch block.

研究者

发起方
KI-AV

相似试验